Biogen Market capitalization 2024

Biogen Market capitalization

31.4 B USD

Biogen Dividend yield

Ticker

BIIB

ISIN

US09062X1037

WKN

789617

In 2024, Biogen's market cap stood at 31.4 B USD, a -24.61% increase from the 41.65 B USD market cap in the previous year.

The Biogen Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2029e11.3364,483.41
2028e11.2564,893.41
2027e10.9166,933.3
2026e10.370,872.93
2025e9.7974,572.61
2024e9.6675,562.3
20239.8474,241.16
202210.1777,613.05
202110.9880,791.56
202013.4586,574
201914.3886,405.89
201813.4586,504.43
201712.2786,722.54
201611.4587,083.7
201510.7688,473.55
20149.787,932.94
20136.9387,621.86
20125.5290,121.38
20115.0590,751.23
20104.7291,521
20094.3891,270.97
20084.190,190.78
20073.1789,410.64
20062.6889,790.22
20052.4284,560.16
20042.2174,910.03

Biogen Aktienanalyse

What does Biogen do?

Biogen Inc. is an American biotechnology company specializing in the development, manufacturing, and marketing of therapeutics for neurodegenerative diseases, autoimmune diseases, and hemophilia. The company was founded in 1978 and is a Fortune 500 company headquartered in Cambridge, Massachusetts. It employs over 7,000 employees worldwide. The origins of Biogen can be traced back to its founding by Charles Weissmann, a Swiss biology professor, and American entrepreneurs Walter Gilbert and Phillip Sharp. The company initially focused on the development of interferon, a protein that protects the body against viruses. However, in the late 1980s, Biogen shifted its research and development efforts towards neurodegenerative diseases. Biogen's business model is based on the discovery and development of new and unique treatments for serious diseases. Through research, the discovery of new compounds, as well as acquisitions and partnerships with other companies, Biogen continually expands its product pipeline. The company also has a strong presence in the global market, selling its products in over 90 countries worldwide. Biogen has sought to expand into multiple areas of the biopharmaceutical industry. The company is divided into three main business areas: neurology, immunology, and hemophilia. In the neurology field, Biogen is a leading provider of drugs for the treatment of severe diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. The company has developed several innovative therapeutics that can either slow down or even halt the progression of these diseases. One example is the drug Aduhelm®, which recently gained approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer's and garnered worldwide attention. In the immunology field, Biogen offers medications for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Biogen is also a major provider of biosimilars, which are replicas of biopharmaceutical drugs developed and manufactured by other companies. Biosimilars can help reduce the cost of patient treatment, particularly in countries with limited healthcare resources. In the hemophilia field, Biogen's offerings include a range of products and services specifically developed for patients with hemophilia. These include clotting factor preparations for the treatment of bleeding, novel clotting factors, and specialized clotting tests. Biogen also invests significantly in the research of new technologies and platforms. The company has formed partnerships with other leading biotech companies such as Ionis Pharmaceuticals and Sangamo Therapeutics to develop innovative technologies like antisense oligonucleotides, genome editing, and gene silencing. Biogen is also a founding member of BioNTech, a German biotechnology company known for its development of mRNA-based vaccines for cancer and infectious diseases. Overall, Biogen has an impressive track record in the development of innovative therapeutics for complex diseases. The company has a strong presence in the global market and aims to expand its product pipeline through research and partnerships. With its high commitment to innovation, Biogen is well-positioned to play a significant role in the biopharmaceutical industry in the future. Biogen ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Biogen revenue by segment

In the annual report of the Biogen share (US09062X1037, 789617, BIIB), it breaks down its revenues into 3 segments: 1. Product, 2. Other, 3. Therapeutics. The Biogen stock (WKN: 789617, ISIN: US09062X1037, Ticker Symbol: BIIB) is a leading investment for investors interested in participating in the Health Care sector.

Market capitalization Details

Exploring Biogen's Market Capitalization

Biogen's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Biogen's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Biogen's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Biogen’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Biogen Stock

What is the current Biogen market capitalization?

The current market capitalization of Biogen is 31.4 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Biogen.

How has the market capitalization of Biogen developed in recent years?

The market capitalization of Biogen has increased/decreased by -24.61% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Biogen?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Biogen?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Biogen have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Biogen pay?

Over the past 12 months, Biogen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biogen is expected to pay a dividend of 0 USD.

What is the dividend yield of Biogen?

The current dividend yield of Biogen is .

When does Biogen pay dividends?

Biogen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biogen?

Biogen paid dividends every year for the past 0 years.

What is the dividend of Biogen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biogen located?

Biogen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biogen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biogen from 3/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/29/2024.

When did Biogen pay the last dividend?

The last dividend was paid out on 3/29/2024.

What was the dividend of Biogen in the year 2023?

In the year 2023, Biogen distributed 0 USD as dividends.

In which currency does Biogen pay out the dividend?

The dividends of Biogen are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Biogen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Biogen

Our stock analysis for Biogen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.